Aortic plaque imaging and monitoring atherosclerotic plaque interventions

Topics in Magnetic Resonance Imaging

Volumn 18, Issue 5, 2007, Pages 349-355

  Momiyama, Yukihiko ^a   Fayad, Zahi A ^b  

^a NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerotic plaque; Coronary artery disease; Lipid lowering; Risk factors

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; PRAVASTATIN; SIMVASTATIN;

ANGIOCARDIOGRAPHY; AORTA ATHEROSCLEROSIS; ARTERY INTIMA PROLIFERATION; ATHEROMA; ATHEROSCLEROTIC PLAQUE; AUTOPSY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE COURSE; HEART INFARCTION; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW;

ANTILIPEMIC AGENTS; AORTIC DISEASES; ARTERIOSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; HUMANS; MAGNETIC RESONANCE IMAGING; RISK FACTORS;

EID: 36348954406     PISSN: 08993459     EISSN: None     Source Type: Journal    
DOI: 10.1097/rmr.0b013e31815a0e5d     Document Type: Review

References (54)

1. Roberts JC Jr, Moses C, Wilkins RH. Autopsy studies in atherosclerosis I: Distribution and severity of atherosclerosis in patients dying without morphologic evidence of atherosclerotic catastrophe. Circulation. 1959;20:511-519.
2. Robert JC Jr, Wilkins RH, Moses C. Autopsy studies in atherosclerosis II: Distribution and severity of atherosclerosis in patients dying with morphologic evidence of atherosclerotic catastrophe. Circulation. 1959;20:520-526.
3. Fazio GP, Redberg RF, Winslow T, et al. Transesophageal echocardiographically detected atherosclerotic aortic plaque is a marker for coronary artery disease. J Am Coll Cardiol. 1993;21:144-150.
4. Khoury Z, Gottlieb S, Stern S, et al. Frequency and distribution of atherosclerotic plaque in thoracic aorta as determined by transesophageal echocardiography in patients with coronary artery disease. Am J Cardiol. 1997;79:23-27.
5. Agmon Y, Khandheria BK, Meissner I, et al. Relation of coronary artery disease and cerebrovascular disease with atherosclerosis of the thoracic aorta in the general population. Am J Cardiol. 2002;89:262-267.
6. Khoury Z, Schwartz R, Gottlieb S, et al. Relation of coronary artery disease to atherosclerotic disease in the aorta, carotid and femoral arteries evaluated by ultrasound. Am J Cardiol. 1997;80:1429-1433.
7. Amanullah AM, Artel BJ, Grossman LB, et al. Usefulness of complex atherosclerotic plaque in the ascending aorta and arch for predicting cardiovascular events. Am J Cardiol. 2002;89:1423-1426.
8. Varga A, Gruber N, Forster T, et al. Atherosclerosis of the descending aorta predicts cardiovascular events: a transesophageal echocardiography study. Cardiovasc Ultrasound. 2004;22:21-27.
9. Fayad ZA, Nahar T, Fallon JT, et al. In vivo magnetic resonance evaluation of atherosclerotic plaques in the human thoracic aorta: a comparison with transesophageal echocardiography. Circulation. 2000;101:2503-2509.
10. Taniguchi H, Momiyama Y, Fayad ZA, et al. In vivo magnetic resonance evaluation of associations between aortic atherosclerosis and both risk factors and coronary artery disease in patients referred for coronary angiography. Am Heart J. 2004;148:137-143.
11. Momiyama Y, Kato R, Fayad ZA, et al. A possible association between coronary plaque instability and complex plaques in abdominal aorta. Arterioscler Thromb Vasc Biol. 2006;26:903-909.
12. Jaffer FA, O'Donnell CJ, Larson MG, et al. Age and sex distribution of subclinical aortic atherosclerosis: A magnetic resonance imaging examination of the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2002;22:849-854.
13. Corti R, Fayad ZA, Fuster V, et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation. 2001;104:249-252.
14. Corti R, Fuster V, Fayad ZA, et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation. 2002;106:2884-2887.
15. Corti R, Fuster V, Fayad ZA, et al. Effects of aggressive versus conventional lipid lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol. 2005;46:106-112.
16. Yonemura A, Momiyama Y, Fayad ZA, et al. Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging. J Am Coll Cardiol. 2005;45:733-742.
17. Ayaori M, Momiyama Y, Fayad ZA, et al. Effect of bezafibrate therapy on atherosclerotic aortic plaques detected by MRI in dyslipidemic patients with hypertriglyceridemia. Atherosclerosis. 2006 Dec 29. Epub ahead of print.
18. Skinner MP, Yuan C, Mitsumori L, et al. Serial magnetic resonance imaging of experimental atherosclerosis detects lesion fine structure, progression and complication in vivo. Nat Med. 1995;1:69-73.
19. Worthley SG, Helft G, Fuster V, et al. High resolution ex vivo magnetic resonance imaging of in situ coronary and aortic atherosclerotic plaque in a porcine model. Atherosclerosis. 2000;150:321-329.
20. Helft G, Worthley SG, Fuster V, et al. Atherosclerotic aortic component quantification by noninvasive magnetic resonance imaging: an in vivo study in rabbits. J Am Coll Cardiol. 2001;37:1149-1154.
21. Shinnar M, Fallon JT, Wehrli S, et al. The diagnostic accuracy of ex vivo MRI for human atherosclerotic plaque characterization. Arterioscler Thromb Vasc Biol. 1999;19:2756-2761.
22. Reed DM, Strong JP, Resch J, et al. Serum lipids and lipoproteins as predictors of atherosclerosis: an autopsy study. Atherosclerosis. 1989;9:560-564.
23. Giral P, Pithois-Merli I, Filitti V, et al. Prevention Cardio-vasculaire en Medecine du Travail METRA Group. Risk factors and early extracoronary atherosclerotic plaques detected by three-site ultrasound imaging in hypercholesterolemic men. Arch Intern Med. 1991;151:950-956.
24. Roberts WC, Ferrans VJ, Levy RI, et al. Cardiovascular pathology in hyperlipoproteinemia: anatomic observations in 42 necropsy patients with normal or abnormal serum lipoprotein patterns. Am J Cardiol. 1973;31:557-570.
25. Overturf M, Sybers H, Schaper J, et al. Hypertension and atherosclerosis in cholesterol-fed rabbits. Atherosclerosis. 1986;59:283-299.
26. Tribouilloy CM, Peltier M, Lannetta-Peltier MC, et al. Relation between low-density lipoprotein cholesterol and thoracic aortic atherosclerosis. Am J Cardiol. 1999;84:603-605.
27. McGill HC. The cardiovascular pathology of smoking. Am Heart J. 1988;115:250-257.
28. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Reseach Group. Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking. JAMA. 1990;264:3018-3024.
29. Tribouilloy C, Peltier M, Andrejak M, et al. Correlation of thoracic aortic atherosclerotic plaque detected by multiplane transesophageal echocardiography and cardiovascular risk factors. Am J Cardiol. 1998;82:1552-1555.
30. Reed D, Reed C, Stemmermann G, et al. Are aortic aneurysms caused by atherosclerosis? Circulation. 1992;85:205-211.
31. Dobrin P, Baker W, Gley W. Elastolytic and collagenolytic studies of arteries. Arch Surg. 1984;119:405-409.
32. Takasu J, Takanashi K, Naito S, et al. Evaluation of morphological changes of the atherosclerotic aorta by enhanced computed tomography. Atherosclerosis. 1992;97:107-121.
33. Ambrose JA, Israel DH. Angiography in unstable angina. Am J Cardiol. 1991;68:78B-84B.
34. Wilson RF, Holida MD, White CW. Quantitative angiographic morphology of coronary stenoses leading to myocardial infarction or unstable angina. Circulation. 1986;73:286-293.
35. Lombardo A, Biasucci LM, Lanza GA, et al. Inflammation as a possible link between coronary and carotid plaque instability. Circulation. 2004;109:3158-3163.
36. Saito D, Shiraki T, Oka T, et al. Morphologic correlation between atherosclerotic lesions of the carotid and coronary arteries in patients with angina pectoris. Jpn Circ J. 1999;63:522-526.
37. McConnell MV, Aikawa M, Maier SE, et al. MRI of rabbit atherosclerosis in response to dietary cholesterol lowering. Arterioscler Thromb Vasc Biol. 1999;19:1956-1959.
38. Helft G, Worthley SG, Fuster V, et al. Progression and regression of atherosclerotic lesions: monitoring with serial noninvasive magnetic resonance imaging. Circulation. 2002;105:993-998.
39. Lima JAC, Desai MY, Steen H, et al. Statin-induced cholesterol lowering and plaque regression after 6 month of magnetic resonance imaging-monitored therapy. Circulation. 2004;110:2336-2341.
40. Adams GJ, Greene J, Vick GW 3rd, et al. Tracking regression and progression of atherosclerosis in human carotid arteries using high-resolution magnetic resonance imaging. Magn Reson Imaging. 2004;22:1249-1258.
41. Zhao XQ, Yuan C, Hatsukami TS, et al. Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study. Arterioscler Thromb Vasc Biol. 2001;21:1623-1629.
42. Chan SK, Jaffer FA, Botnar RM, et al. Scan reproducibility of magnetic resonance imaging assessment of aortic atherosclerosis burden. J Cardiovasc Magn Reson. 2001;3:331-338.
43. Li AE, Kamel I, Rando F, et al. Using MRI to assess aortic wall thickness in the multiethnic study of atherosclerosis: distribution by race, sex and age. Am J Roentgenol. 2004;182:593-597.
44. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomized, double-blind trial. Lancet. 2001;357:577-581.
45. Nissen SE, Tuzeu EM, Schoenhagen P, et al. for the REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071-1080.
46. Ericsson CG, Hamsten A, Nilsson J, et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 1996;347:849-853.
47. Vallilainen J, Steiner G, Ansquer JC, et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: The Diabetes Atherosclerosis Intervention Study (DAIS). Circulation. 2003;107:1733-1737.
48. Corti R, Osende J, Hutter R, et al. Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: in vivo demonstration by high-resolution MRI. Atherosclerosis. 2007;190:106-113.
49. Berenson GS, Srinivasan SR, Bao W, et al. for the Bogalusa Heart Study. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. N Engl J Med. 1998;338:1650-1656.
50. Reed DM, Strong JP, Resch J, et al. Serum lipids and lipoproteins as predictors of atherosclerosis: an autopsy study. Arteriosclerosis. 1989;9:560-564.
51. Fuster V, Moreno PR, Fayad ZA, et al. Atherothrombosis and high-risk plaque: Part I. J Am Coll Cardiol. 2005;46:937-954.
52. Ruotolo G, Ericsson CG, Tettamanti C, et al. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol. 1998;32:1648-1656.
53. Ikewaki K, Noma K, Tohyama J, et al. Effects of bezafibrate on lipoprotein subclass and inflammatory markers in patients with hypertriglyceridemia: a nuclear magnetic resonance study. Int J Cardiol. 2005;101:441-447.
54. Soedamah-Muthu SS, Colhoun HM, Thomason MJ, et al. The CARDS investigators. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischemic heart disease. Atherosclerosis. 2003;167:243-255.